Ballicules.com

Tropicamide

MYDRIACYL

Pronunciation: troe-PIK-a-mide

Tropicamide ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Tropicamide ballicule

What it isShort-acting ophthalmic antimuscarinic that produces mydriasis and cycloplegia for eye examination.

Why this oneRapid onset and brief duration allow faster visual recovery than atropine or cyclopentolate.

What limits itMay transiently raise intraocular pressure and can cause systemic anticholinergic CNS effects, especially in children; punctal occlusion reduces absorption.

Tropicamide molecular structure (skeletal formula)
Molecular structure: Tropicamide

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Mydriasis/cycloplegia for refractionAdults and pediatric1–2 drops 1% in eye(s), repeat in 5 min1–2 drops 1%additional drop at 20–30 min to prolong effect

Renal Undefined

Hepatic Undefined

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy Animal reproduction studies not conducted; use only if clearly needed

Lactation Undefined

Cost

Tropicamide (MYDRIACYL)
Strength#/mogeneric $/unitCostPlus
0.5 %dropsper unitnot offered
1 %dropsper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Tropicamide is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry1982

NO BOXED WARNINGS

Principal riskprecipitation of acute angle-closure glaucoma

Classes and tags

Clinical profile

Therapeutic safety burden0 / 4
Overdose danger0 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism4 / 4
Embryofetal risk0 / 4

Legacy pregnancy categoryC

Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.

Open Tropicamide in the interactive console ↗